SNY · Sanofi
$42.77
+0.12% last session
End-of-day data · close of 2026-09-11
Market cap
$102B
Enterprise value
$120B
Trailing P/E
22.7
Forward P/E
7.9
Dividend yield
6.0%
Beta
0.28
Avg volume
3M
Employees
75K
Daily Change %
0.12%
5 Days Change
-3.14%
10 Days Change
-3.40%
30 Days Change
-1.63%
60 Days Change
-1.49%
Month to Day Change
-3.43%
Year to Day Change
-6.67%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SNY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-01-16
Latest call per bank · past 12 months
UBS
Neutral$0.00
-100.0% vs priceBarclays
Equal-Weight$0.00
-100.0% vs priceJP Morgan
Neutral$0.00
-100.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-01-16 | UBS | Downgrade | Buy → Neutral | $0.00 |
| 2026-01-06 | Barclays | Downgrade | Overweight → Equal-Weight | $0.00 |
| 2025-12-09 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2025-12-08 | JP Morgan | Downgrade | Overweight → Neutral | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.6% below the 50-day MA ($43.93).
- Price vs 200-day MA: Trading 3.3% below the 200-day MA ($44.25).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.31) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($41.31).
SNY Price Chart
Loading chart for SNY…
Fundamentals
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.